ACON vs. OPGN, BPTH, GLMD, NAOV, CMND, OSAP, PXMD, DRMA, WINT, and SLRX
Should you be buying Aclarion stock or one of its competitors? The main competitors of Aclarion include OpGen (OPGN), Bio-Path (BPTH), Galmed Pharmaceuticals (GLMD), NanoVibronix (NAOV), Clearmind Medicine (CMND), ProSomnus (OSAP), PaxMedica (PXMD), Dermata Therapeutics (DRMA), Windtree Therapeutics (WINT), and Salarius Pharmaceuticals (SLRX). These companies are all part of the "medical" sector.
Aclarion (NASDAQ:ACON) and OpGen (NASDAQ:OPGN) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their community ranking, institutional ownership, valuation, analyst recommendations, media sentiment, earnings, profitability, risk and dividends.
Aclarion has higher earnings, but lower revenue than OpGen.
Aclarion has a beta of 0.4, suggesting that its stock price is 60% less volatile than the S&P 500. Comparatively, OpGen has a beta of -0.56, suggesting that its stock price is 156% less volatile than the S&P 500.
OpGen received 300 more outperform votes than Aclarion when rated by MarketBeat users. However, 100.00% of users gave Aclarion an outperform vote while only 55.74% of users gave OpGen an outperform vote.
OpGen has a net margin of -852.18% compared to Aclarion's net margin of -10,246.33%. OpGen's return on equity of -316.30% beat Aclarion's return on equity.
7.5% of Aclarion shares are owned by institutional investors. Comparatively, 2.7% of OpGen shares are owned by institutional investors. 22.3% of Aclarion shares are owned by insiders. Comparatively, 1.3% of OpGen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
In the previous week, OpGen had 3 more articles in the media than Aclarion. MarketBeat recorded 5 mentions for OpGen and 2 mentions for Aclarion. Aclarion's average media sentiment score of 0.02 beat OpGen's score of -0.22 indicating that Aclarion is being referred to more favorably in the media.
Summary
Aclarion beats OpGen on 7 of the 13 factors compared between the two stocks.
Get Aclarion News Delivered to You Automatically
Sign up to receive the latest news and ratings for ACON and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ACON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aclarion Competitors List
Related Companies and Tools
